All Releases |
|
Feb 8, 2005
Harris & Harris Group Invests In Nextreme Thermal Solutions, Inc.
|
41.1 KB
|
| |
Harris & Harris Group, Inc. announced today that it has invested $1 million as part of an $8 million Series A Preferred round of financing by privately held Nextreme Thermal Solutions, Inc. The investor syndicate was led by Spacevest and Aurora Funds and included Harris & Harris Group and RTI International. The company is headquartered in Researc...
|
Read more
|
|
Feb 4, 2005
Businessweek Article On Nanotech
|
56.4 KB
|
| |
Shareholders of Harris & Harris Group, Inc., may be interested to read the cover article of the current issue of BusinessWeek, dated February 14, 2005, by Stephen Baker and Adam Aston, entitled, "Nanotech," which mentions Harris & Harris Group.
Harris & Harris Group is a publicly traded venture capital company that now makes initi...
|
Read more
|
|
Feb 1, 2005
Harris & Harris Group Invests In Cambrios Technologies Corporation
|
41.2 KB
|
| |
Harris & Harris Group, Inc. announced today that it has invested in Cambrios Technologies Corporation, as part of a Series B funding round the company recently closed. Harris & Harris Group participated in this round of financing along with other new Series B investors, In-Q-Tel and Headland Ventures, and returning Series A investors, Alloy Ventur...
|
Read more
|
|
Jan 27, 2005
Harris & Harris Group Notes 2004 Results Of NeuroMetrix
|
42.8 KB
|
| |
Shareholders of Harris & Harris Group, Inc., may be interested to note that NeuroMetrix, Inc. (Nasdaq: NURO), released today its results for the year ended December 31, 2004. Total revenues increased by 95 percent, from $9,167,557 in 2003 to $17,920,089 in 2004. For the quarter ended December 31, total revenues increased by 101 percent, from $2,8...
|
Read more
|
|
Jan 19, 2005
Harris & Harris Group Notes Nanosys - Sharp Fuel Cell Agreement
|
40.8 KB
|
| |
Shareholders of Harris & Harris Group, Inc., may be interested to read the press release from Nanosys, Inc. (www.nanosysinc.com), dated January 18, 2005, announcing its collaborative agreement with Sharp Corporation of Osaka, Japan, to develop nanotechnology-enabled fuel cells incorporating Nanosys's nanostructure technology.
Harris & Ha...
|
Read more
|
|
Jan 18, 2005
Article In Scientific American On Nantero
|
48.8 KB
|
| |
Shareholders of Harris & Harris Group, Inc., may be interested to read in the February, 2005, issue of Scientific American the article on Nantero, Inc., by Gary Stix, on pages 82-85, entitled, "Nanotubes in the Clean Room," and referenced on the cover of the issue as, "Nanotube Fabric for Microelectronics."
Harris & Harris Group has an i...
|
Read more
|
|
Jan 10, 2005
Television Series On Nanotechnology
|
40.1 KB
|
| |
Shareholders of Harris & Harris Group, Inc., may be interested in viewing the week-long series (January 10 through January 14) on nanotechnology on Report on Business Television, Canada's business news television station. Canadian and non-Canadian viewers can access the program on the internet to watch replays of the interviews (http://www.robtv.c...
|
Read more
|
|
Jan 4, 2005
Article In The Economist
|
56.6 KB
|
| |
Shareholders of Harris & Harris Group, Inc. may be interested to read the section of the January 1st issue of The Economist entitled, "Small Wonders: A Survey of Nanotechnology."
Harris & Harris Group is a publicly traded venture capital company that now makes initial investments exclusively in tiny technology, including nanotech...
|
Read more
|
|
Dec 31, 2004
HARRIS & HARRIS GROUP NOTES PFIZER APPROVAL TO MARKET LYRICA
|
42.8 KB
|
| |
Harris & Harris Group, Inc., noted today that Pfizer Inc. (NYSE: PFE) has announced that it has received FDA approval to market Lyrica for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia. In September, Eli Lilly's (NYSE: LLY) drug, Cymbalta, had become the first drug approved to tr...
|
Read more
|
|
Dec 16, 2004
HARRIS & HARRIS GROUP WILL NOT DECLARE A DEEMED DIVIDEND FOR 2004
|
42.3 KB
|
| |
Harris & Harris Group, Inc., announced today that owing to the availability for tax purposes of a prior year's net capital loss carryover, the Company has determined that it will not have taxable net long-term capital gain income for 2004. The Company will have $520,246.35 net long-term capital gains for book purposes for 2004, which we will retai...
|
Read more
|
|
Dec 15, 2004
HARRIS & HARRIS GROUP DECLARES DEEMED DIVIDEND
|
44.0 KB
|
| |
Harris & Harris Group, Inc. announced today that its Board of Directors, in accordance with rules governing a Regulated Investment Company ("RIC") under Sub-Chapter M of the Internal Revenue Code, has declared a designated undistributed capital gain dividend (also known as a deemed dividend) for 2004.
This deemed dividend will be an amou...
|
Read more
|
|
Nov 30, 2004
HARRIS & HARRIS GROUP INVESTS IN SOLAZYME, INC.
|
42.3 KB
|
| |
Harris & Harris Group, Inc. announced today that it has invested $310,000 in Solazyme, Inc., as part of a larger funding round the company recently closed. Solazyme is a privately held company based in Menlo Park, California, and Daniel V. Leff, a Managing Director and Executive Vice President of Harris & Harris Group, Inc., has joined the Solazym...
|
Read more
|
|
Nov 15, 2004
SMALL TIMES MAGAZINE NAMES BEST OF SMALL TECH
|
59.3 KB
|
| |
Today, Small Times Magazine released its third annual performance review of the people, products and companies in micro and nanotechnology. The Awards are based on accomplishments between September 1, 2003, and October 1, 2004.
Molecular Imprints, Inc., won the Best of Small Tech Award: Company of the Year. Harris & Harris Gr...
|
Read more
|
|
Nov 8, 2004
NANTERO NAMED NANOTECHNOLOGY LEADER BY SCIENTIFIC AMERICAN
|
60.4 KB
|
| |
Shareholders of Harris & Harris Group, Inc., may be interested to know that Nantero, Inc. (www.nantero.com), has been named by Scientific American magazine as a Business Leader within the "Scientific American 50" -- the magazine's annual list recognizing outstanding acts of leadership in science and technology from the past year. Nantero ha...
|
Read more
|
|
Oct 27, 2004
HARRIS & HARRIS GROUP REPORTS BALANCE SHEET FOR NINE MONTHS ENDED SEPTEMBER 30, 2004
|
43.8 KB
|
| |
Gross assets, net assets and net asset value per share increased during the quarter, reflecting both a successful follow-on offering of the Company's shares and a successful initial public offering (IPO) of one of the Company's portfolio companies, NeuroMetrix, Inc. (Nasdaq: NURO). In the Company's oversubscribed follow-on offering, underwritten b...
|
Read more
|
|
Oct 6, 2004
NANOTECHNOLOGY ARTICLE IN BUSINESSWEEK
|
57.1 KB
|
| |
Shareholders of Harris & Harris Group, Inc. may be interested to read the article entitled, "Universe in a Grain of Sand," by Stephen Baker and Adam Aston, in the October 11, 2004, issue of BusinessWeek. The article mentions one of our portfolio companies, privately held Nantero, Inc.
Harris & Harris Group is a publicly traded v...
|
Read more
|
|
Oct 5, 2004
HARRIS & HARRIS GROUP NOTES AWARD OF SUB-CONTRACT TO NANOSYS
|
42.5 KB
|
| |
Harris & Harris Group, Inc. noted today that Nanosys, Inc. signed an $8.2 million five year sub-contract awarded by Science Applications International Corporation (SAIC) to develop undisclosed sub-system components based on Nanosys' proprietary nanotechnology platform for use in systems for the U.S. Government. Under this contract, Nanosys will re...
|
Read more
|
|
Sep 30, 2004
ARTICLE ON CHLOROGEN IN BIOVENTURE VIEW
|
57.6 KB
|
| |
Shareholders may be interested in reading the article on page 15 of the September 10, 2004 publication Bioventure View entitled, "Chlorogen: the art of pharma-synthesis." The article discusses Chlorogen's chloroplast-based protein production technology and its commercialization strategy.
Privately held Chlorogen, Inc. is develop...
|
Read more
|
|
Sep 29, 2004
HARRIS & HARRIS GROUP INVESTS IN CRYSTAL IS, INC.
|
41.0 KB
|
| |
Harris & Harris Group, Inc. announced today that it has invested $200,000 as part of a $5 million Series A Preferred round of financing by privately held Crystal IS, Inc. The investor syndicate was led by Arch Venture Partners and included JVP, 3i and Harris & Harris Group.
Crystal IS is a supplier of ultra-low defect density native a...
|
Read more
|
|
Sep 8, 2004
HARRIS & HARRIS GROUP NOTES FDA APPROVAL OF CYMBALTA
|
41.9 KB
|
| |
Harris & Harris Group, Inc. noted today that the U.S. Food and Drug Administration (FDA) has approved Eli Lilly's Cymbalta (duloxetine HCI) for the management of pain associated with diabetic peripheral neuropathic pain (DNP). DNP is a symptom of nerve damage that affects up to five million Americans, Eli Lilly announced yesterday. Cymbalta is t...
|
Read more
|
|
